Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | LPO | P22079 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28224567 | 0.82 | IDO1 (0.56) | IDO1AGXTTAAR1CHRM2CHRM1 | |
| SCHEMBL28743543 | 0.82 | IDO1 (0.56) | IDO1AGXTTAAR1CHRM2CHRM1 | |
| SCHEMBL28084246 | 0.82 | IDO1 (0.56) | IDO1AGXTTAAR1CHRM2CHRM1 | |
| SCHEMBL29624521 | 0.82 | IDO1 (0.56) | IDO1AGXTTAAR1CHRM2CHRM1 | |
| SCHEMBL27610564 | 0.82 | IDO1 (0.56) | IDO1AGXTTAAR1CHRM2CHRM1 | |
| SCHEMBL29382328 | 0.81 | ALDH1A1 (0.60) | IDO1AGXTTAAR1CHRM2CHRM1 | |
| SCHEMBL2091147 | 0.81 | ALDH1A1 (0.60) | IDO1AGXTTAAR1CHRM2CHRM1 | |
| SCHEMBL6201718 | 0.81 | PPARA (0.37) | IDO1AGXTTAAR1CHRM2CHRM1 | |
| SCHEMBL8305017 | 0.81 | TAAR1 (0.58) | IDO1AGXTTAAR1CHRM2CHRM1 | |
| SCHEMBL12335546 | 0.80 | IDO1 (0.50) | IDO1AGXTTAAR1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505156-B1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | CONSORTIUM ELEKTROCHEM IND (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2005-02-10 | — | — | US | disclosed |
| EP-1505156-A1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | Consortium für elektrochemische Industrie GmbH (DE) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | LIPC, LIPE, LIPA | IDO1 4255/4885AGXT 88/4885TAAR1 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.